On the heels of a major deal with Bristol-Myers Squibb Co. to develop its treatment called E2F Decoy for preventing post-surgery vein-graft failure, Corgentech Inc. has registered an initial public offering to raise $86.25 million. (BioWorld Today)

In its second deal of the week, Merck & Co. Inc. tapped Swiss firm Actelion Inc. for a potential $272 million agreement to develop new classes of renin inhibitors for cardio-renal diseases. (BioWorld Today)

Less than a year after entering a potential $545 million deal with GlaxoSmithKline plc to find new, long-acting beta2-agonists for respiratory diseases, Theravance Inc. said a pair of early Phase II studies yielded positive results. (BioWorld Today)

Maxim Pharmaceuticals Inc. nailed down a potential $27 million licensing deal centered on its apoptosis-inducing cancer compounds with Myriad Genetics Inc. (BioWorld Today)